Zacks Investment Research·Sep 16, 2026
Here's Why Omnicell (OMCL) is a Strong Value StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Omnicell appears to be emerging from a cyclical trough, with revenue rebounding 7.4% YoY in 2026Q2 and gross margin expanding 1,030 basis points from 38.7% in 2024Q1 to 49.0% in 2026Q2, driving operating leverage and a return to profitability. The balance shee...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.94+101.1% vs $0.47 | $312M+0.6% vs $310M |
Q2 2026 Apr 28, 2026 | $0.55+66.7% vs $0.33 | $310M+1.9% vs $304M |
Q1 2026 Feb 5, 2026 | $0.40-14.9% vs $0.47 | $314M+0.2% vs $313M |
Q4 2025 Oct 30, 2025 | $0.51+41.7% vs $0.36 | $311M+5.1% vs $296M |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Benchmark OMCL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Omnicell, Inc. (OMCL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $32.99 | $1.5B | 744.70 | 6.53% | 0.17% | 0.17% | — | |
| $182.52 | $50.29B | 31.31 | 8.23% | 4.52% | 3.79% | — | |
| $85.05 | $9.69B | 26.01 | 4.03% | 2.96% | 8.38% | — | |
| $880.50 | $104.96B | 22.94 | 12.36% | 1.12% | — | — | |
| $221.27 | $51.82B | 30.60 | 299.31% | 0.67% | — | — | |
| $270.75 | $43.98B | 49.77 | 16.34% | 29.34% | 14% | — |
Omnicell, Inc. (OMCL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Omnicell, Inc. (OMCL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 1, 2026·SEC
May 26, 2026·SEC
Get notified when OMCL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Omnicell, Inc. (OMCL) stock FAQ — growth, dividends, profitability & financials explained
Omnicell, Inc. (OMCL) reported $1.25B in revenue for fiscal year 2025. This represents a 1751% increase from $67.4M in 2000.
Omnicell, Inc. (OMCL) grew revenue by 6.5% over the past year. This is steady growth.
Yes, Omnicell, Inc. (OMCL) is profitable, generating $39.1M in net income for fiscal year 2025 (0.2% net margin).
Omnicell, Inc. (OMCL) has a return on equity (ROE) of 0.2%. This is below average, suggesting room for improvement.
Omnicell, Inc. (OMCL) generated $141.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
